Cerebrolysin
WellnessAlso known as: FPE 1070, Cerebral Lysate
Well-StudiedWhat is Cerebrolysin?
A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Approved in over 40 countries (but not the US) for stroke recovery, traumatic brain injury, and dementia. It has a significant evidence base but remains controversial in Western neurology.
How it works
Contains a mixture of neurotrophic peptides that mimic the activity of naturally occurring nerve growth factors (BDNF, GDNF, NGF, CNTF). These peptides cross the blood-brain barrier and promote neuronal survival, synaptic plasticity, neurogenesis, and repair of damaged neural circuits.
What marketers claim
- ▸makes you smarter
- ▸cures Alzheimer's disease
- ▸repairs all brain damage
- ▸nootropic with no downsides
What evidence supports
- ✓multiple RCTs show modest improvement in cognitive and global function in Alzheimer's patients
- ✓evidence of benefit in acute ischemic stroke recovery in several clinical trials
- ✓approved for neurological indications in over 40 countries including EU member states
- ✓neurotrophic and neuroprotective effects demonstrated in preclinical models
- ✓Cochrane review found evidence of benefit in vascular dementia but called for larger trials
Research evidence
Key studies on Cerebrolysin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled trial
Finding: Cerebrolysin significantly improved cognitive function (ADAS-cog) and clinical global impression compared to placebo after 24 weeks. Effects were sustained at follow-up.
Limitation: Moderate sample size. Conducted primarily in Eastern European centers. Dropout rate was notable.
Cerebrolysin in acute ischemic stroke (CASTA trial)
Finding: No significant difference in primary outcome (mRS at 90 days) between Cerebrolysin and placebo. Post-hoc analysis suggested potential benefit in patients with more severe strokes (NIHSS > 12).
Limitation: Failed to meet its primary endpoint. The post-hoc subgroup analysis, while intriguing, is hypothesis-generating only and not considered confirmatory evidence.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Day 1-7
Typically administered as daily IV infusions in clinical settings. Some patients report mild headache or dizziness during the initial treatment course.
Week 2-4
Clinical trials typically use 4-week treatment courses. Cognitive improvements may begin to emerge in dementia patients during this period.
Month 1-3
Post-stroke patients may show measurable improvements in neurological function scores. Alzheimer's patients may show stabilization or modest improvement in cognitive assessments.
Month 6+
Some studies suggest sustained benefit after treatment cessation. Repeat treatment courses are commonly used in clinical practice.
Safety notes & concerns
Full safety guide →- ⚠not FDA-approved — the FDA has not reviewed it for any indication
- ⚠porcine brain-derived product raises theoretical prion disease concerns, though no cases reported
- ⚠requires intravenous or intramuscular injection — not suitable for self-administration
- ⚠side effects include dizziness, headache, and injection site reactions
- ⚠many key trials were conducted in countries with less rigorous regulatory standards
- ⚠large definitive phase III trials in stroke (CASTA) showed mixed results
Pairs well with
Use caution with
Frequently asked questions
Why isn't Cerebrolysin approved in the US?
The manufacturer (EVER Pharma) has not submitted a New Drug Application to the FDA. This is likely a commercial decision — the large-scale clinical trials required for FDA approval are extremely expensive, and as a complex biological mixture, Cerebrolysin faces additional regulatory hurdles compared to single-molecule drugs.
Is there a risk of prion disease from Cerebrolysin?
Cerebrolysin is derived from porcine (pig) brain tissue, which theoretically raises prion concerns. However, the manufacturing process includes purification steps designed to remove larger proteins, and there have been no reported cases of prion transmission in decades of clinical use across millions of patients.
Can Cerebrolysin be used as a nootropic in healthy people?
Most clinical evidence is in patients with neurological conditions (stroke, dementia, TBI). There is very limited data on cognitive enhancement in healthy individuals. Using an injectable porcine brain extract for nootropic purposes carries a risk-benefit profile that most physicians would consider unfavorable for healthy people.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Cerebrolysin
Last updated: 2025-04-09
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.